This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| Adipotide | Enicepatide (CT-388) | |
|---|---|---|
| Highest evidence tier on the page | E3 Early human evidence Small, open-label, uncontrolled, case series, or a registered trial with no published results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not stated | Not stated |
| Research area | Metabolic and incretin | Metabolic and incretin |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C111H206N36O28S2 (per PubChem) | C226H345FN48O67, per a peer-reviewed phase 1 publication. |
| Molar mass | Not independently re-derived for this entry from an authoritative source; PubChem lists the compound under the formula above without an easily accessible listed molecular weight in the pages reviewed. Regard any specific mass figure seen elsewhere online as unverified until confirmed against PubChem directly. | Approximately 4,825 Da, per the same publication; a commercial vendor lists 4,825.44 Da, consistent within rounding. |
| CAS number | 859216-15-2 | Not reliably established; two secondary sources conflict (2919675-94-6 vs. 2869147-44-2) with no primary registry confirmation of either. |
| Registered trials on this site | 1 in the tracker | 6 in the tracker |
| Furthest registered phase | Phase 1 | Phase 3 |
| Trials currently active | 0 | 4 |
| Trial sponsors | M.D. Anderson Cancer Center | Hoffmann-La Roche, Carmot Therapeutics, Inc. |
| What is not known | Whether Adipotide is safe or effective in a general, non-cancer, human obesity population; no such trial has ever been conducted. The specific human doses used in the one Phase I trial that was conducted (NCT01262664), and its results, since the trial was terminated with only... | The low- and middle-dose results from both phase 2 trials remain unreported in any source checked; only the top, 24 mg, dose's results have been disclosed publicly. The exact phase 3 dosing regimen has not been disclosed. The 24-week phase 1 extension cohort's exact dose... |
Full pages: Adipotide and Enicepatide (CT-388). See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
